Two courses of four weekly infusions of rituximab with or without interferon-α2a: Final results from a randomized phase III study in symptomatic indolent B-cell lymphomas

Leukemia and Lymphoma

Volumn 56, Issue 9, 2015, Pages 2598-2607

  Kimby, Eva ^a   Östenstad, Björn ^b   Brown, Peter ^c   Hagberg, Hans ^d   Erlanson, Martin ^e   Holte, Harald ^b   Linden, Ola ^f   Johansson, Ann Sofie ^e   Ahlgren, Tomas ^g   Wader, Karin ^h   Wahlin, Björn Engelbrekt ^a   Delabie, Jan ^b   Sundström, Christer ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Rigshospitalet   (Denmark)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

biologic therapy; follicular lymphoma; indolent lymphoma; interferon a2a; long term survival; Rituximab

Indexed keywords

ALPHA2A INTERFERON; RITUXIMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CHILL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; INDOLENT B CELL LYMPHOMA; INFLUENZA; INTENTION TO TREAT ANALYSIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERICARDITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTIC SHOCK; TIME TO TREATMENT; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, B-CELL; MIDDLE AGED; PATHOLOGY; REMISSION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILLS; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON-ALPHA; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REMISSION INDUCTION; RITUXIMAB; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946049367     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1014363     Document Type: Article

References (34)

1. Ardeshna KM, Smith P, Norton A, et al. Long-Derm effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-522.
2. Solal-Celigny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-Dumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012; 30: 3848-3853.
3. Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia 2014; 28: 1388-1395.
4. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140-147.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
6. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052-3056.
7. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
8. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
9. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
10. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
11. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-4831.
12. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452.
13. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582-1589.
14. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 2013; 122: 981-987.
15. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-Analysis. J Natl Cancer Inst 2007; 99: 706-714.
16. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
17. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416-4423.
18. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-Analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215-2223.
19. DallOzzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664-4669.
20. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-1157.
21. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642.
22. Basham TY, Palladino MA, Badger CC, et al. Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B-And T-cell lymphomas. Cancer Res 1988; 48: 4196-4200.
23. Brown SL, Miller RA, Horning SJ, et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651-661.
24. Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-Alpha-2a. Clin Cancer Res 2000; 6: 2644-2652.
25. Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-Alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951-958.
26. Kimby E, Jurlander J, Geisler C, et al. Long-Derm molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008; 49: 102-112.
27. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
28. Martinelli G, Schmitz SF, Utiger U, et al. Long-Derm follow-up of patients with follicular lymphoma receiving single-Agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28: 4480-4484.
29. Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-And-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014; 4: 424-435.
30. Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-Dreatment trial for low-Dumor burden follicular lymphoma: Eastern Cooperative Oncology Group Protocol E4402. J Clin Oncol 2014; 32: 3096-3102.
31. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
32. Bachy E, Houot R, Morschhauser F, et al. Long-Derm follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 2013; 7: 1107-1114.
33. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013; 31: 3272-3278.
34. Ban-Hoefen M, Vanderplas A, Crosby-Dhompson AL, et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 2013; 163: 487-495.